Suzhou Zelgen Biopharmaceuticals Co.,Ltd. (SHA: 688266)
China
· Delayed Price · Currency is CNY
62.50
+0.06 (0.10%)
Nov 19, 2024, 3:00 PM CST
Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Company Description
Suzhou Zelgen Biopharmaceuticals Co.,Ltd. researches and develops, manufactures, and sells medicines in the People's Republic of China.
It offers donafenib tablets; recombinant human thrombin for topincal use; jacktinib tablets; and recombinant human thyroid-stimulating hormone for injection; obeticholic acid magnesium tablets; ZG19018 tablets; ZG005 powder for injection; and alkotinib capsules for the treatment of liver cancer, non-small cell lung cancer, small cell lung cancer, colorectal cancer, thyroid cancer, and neuroendocrine cancer, as well as multiple therapeutic areas, such as bleeding, hepatobiliary diseases, and autoimmune diseases.
The company was founded in 2009 and is based in Kunshan, the People's Republic of China.
Suzhou Zelgen Biopharmaceuticals Co.,Ltd.
Country | China |
Founded | 2009 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 867 |
CEO | Zelin Sheng |
Contact Details
Address: No. 209, Chenfeng Road Kunshan, 215300 China | |
Phone | 86 512 5701 8310 |
Website | zelgen.com |
Stock Details
Ticker Symbol | 688266 |
Exchange | Shanghai Stock Exchange |
Fiscal Year | January - December |
Reporting Currency | CNY |
ISIN Number | CNE100003RP1 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Zelin Sheng | Chairman of the Board and GM |
Gang Huang | Chief Financial Officer and Deputy GM |
Zeqi Sheng | Chief Scientific Officer |
Huiping Lu | Executive Vice President and Director |
Jisheng Wu | Director and Deputy GM |
Binhua Lv | Deputy General Manager and Director |
Qingping Gao | Deputy GM and Board Secretary |